Pheochromocytomas, which are catecholamine-secreting tumors of neural crest origin, are frequently hereditary 1 . However, the molecular basis of the majority of these tumors is unknown 2 . We identified the transmembrane-encoding gene TMEM127 on chromosome 2q11 as a new pheochromocytoma susceptibility gene. In a cohort of 103 samples, we detected truncating germline TMEM127 mutations in approximately 30% of familial tumors and about 3% of sporadic-appearing pheochromocytomas without a known genetic cause. The wild-type allele was consistently deleted in tumor DNA, suggesting a classic mechanism of tumor suppressor gene inactivation. Pheochromocytomas with mutations in TMEM127 are transcriptionally related to tumors bearing NF1 mutations and, similarly, show hyperphosphorylation of mammalian target of rapamycin (mTOR) effector proteins. Accordingly, in vitro gain-of-function and loss-of-function analyses indicate that TMEM127 is a negative regulator of mTOR. TMEM127 dynamically associates with the endomembrane system and colocalizes with perinuclear (activated) mTOR, suggesting a subcompartmental-specific effect. Our studies identify TMEM127 as a tumor suppressor gene and validate the power of hereditary tumors to elucidate cancer pathogenesis.
Using an integrative genomics strategy that involved linkage analysis, global expression profiling and high-density copy number mapping, we previously defined a pheochromocytoma susceptibility locus in chromosome 2q11, which we named FP (familial pheochromocytoma) 3 . Identification of other affected individuals in the original kindred allowed us to establish a dominant model of transmission ( Supplementary Fig. 1 ), and additional linked families led us to redefine the limits of the FP locus to a region containing 205 genes (NCBI Build 35.1; Supplementary Table 1) spanning the 19.62 Mb between 94.81 Mb and 114.43 Mb. We used tumor DNA from one of the affected individuals (the index case of family 1) as a template for exon-based sequencing, as previously described 4 . Using this approach, we identified a splice-site variant (IVS3-2A<C) in the provisional transmembrane protein-encoding gene TMEM127, also known as FLJ20507 ( Table 1 and Supplementary Fig. 2a,b) . This mutation was also present in this individual's germline DNA, as well as in each of six other affected siblings, but not in samples from two unaffected sibs.
We next sequenced germline and/or tumor DNA from an additional 102 index cases with pheochromocytomas, of which 19 had a clear familial history and 83 were apparently sporadic. We detected six other TMEM127 mutations in these samples ( Table 1 and Supplementary Fig. 2c ). Six of the seven TMEM127 variants were splice-site or nonsense mutations predicted to interrupt the protein reading frame prematurely ( Table 1 and Supplementary  Fig. 2a,b) . In total, we detected four TMEM127 variants (including that found in the index case) among 12 families without mutations in other pheochromocytoma susceptibility genes (Supplementary Table 2 and Supplementary Fig. 2a,b) . We identified the other three mutations among the 'sporadic' cases that were wild-type for known pheochromocytoma-related genes. One of the subjects was adopted, and thus heredity status was unknown (patient 2; Table 1 ), and the other two individuals reported no family history of pheochromocytoma (patients 4 and 7; Table 1 ). In all affected individuals, mutations were detected in the corresponding germline DNA and, when available, in DNA from other relatives with pheochromocytoma ( Table 1) . One of the identified mutations,(IVS3-2A<C), was detected in two separate families (families 1 and 5; Table 1 ). Haplotype analysis of tumor DNA excluded a common ancestor for these two families (Supplementary Table 3 ). None of the sequence changes found in the pheochromocytoma samples were identified in a group of 1,064 ethnically matched alleles, although known and previously unreported polymorphic variants were detected in these control samples (Supplementary Table 4) .
We examined loss of heterozygosity (LOH) at the TMEM127 locus in 35 pheochromocytomas: all TMEM127-mutant tumors tested (n = 19, including samples from multiple affected individuals from the same family or samples from bilateral tumors) had LOH, in contrast with only 2 of 16 wild-type TMEM127 samples (P = 5. Table 5 ). In each TMEM127-mutant pheochromocytoma, the wild-type allele was lost (Supplementary Fig. 2a) , which is in agreement with a two-hit model of tumor suppressor inactivation. The only missense mutation (V90M) in this series targeted an amino acid conserved among putative mammalian TMEM127 orthologs. As only germline DNA was available from the sample carrying this mutation, LOH status could not be determined.
We next measured TMEM127 transcripts in pheochromocytomas and found that TMEM127-mutant samples (n = 7) expressed only 22% of the transcript levels detected in pheochromocytomas of various genetic backgrounds with wild-type TMEM127 sequence (n = 16, P = 0.002; Supplementary Fig. 2d ). This degree of downregulation suggests instability of the mutant transcript rather than simply low expression due to loss of one allele. RNA was unavailable from two tumor samples that had LOH at 2q11 but no TMEM127 mutation.
Clinically, subjects with TMEM127 mutations developed pheochromocytomas at 45.3 years of age on average, which is similar to the mean age at diagnosis of sporadic pheochromocytomas (43.6-43.9 years) 1,5 but notably older than the mean age at diagnosis of syndromic cases (24.9-30.2 years) 1, 5 . All tumors arose from the adrenal medulla, and they were bilateral in approximately half of cases ( Table 1) . No malignancies, as defined by the presence of metastasis in nonchromaffin-derived tissues, or recurrences were detected during follow-up of the affected subjects (4-16 years after initial diagnosis). Four mutation carriers from family 1 ( Table 1 ) remain without clinical disease at ages ranging from 43 to 58 years, but a clear picture of the actual penetrance and phenotypic spectrum associated with TMEM127 mutations awaits larger studies. Taken together, the data above suggest that TMEM127 mutations are associated with pheochromocytoma predisposition and that TMEM127 has features of a classic tumor suppressor gene.
TMEM127 is predicted to encode a protein with three transmembrane regions (Supplementary Fig. 2c ) and no clearly recognizable functional domains. Its sequence is highly conserved throughout evolution, and putative orthologs can be identified in many species, from mammals to fish (Supplementary Fig. 3a) . Human TMEM127 is broadly expressed both in normal tissue (Supplementary Fig. 3b ) and in a diverse group of cancer cell lines 6 (Supplementary Fig. 3c) , with variable transcription levels that may reflect tissue of origin. Likewise, its putative mouse ortholog is widely expressed from an early postnatal age through adulthood (Supplementary Fig. 3d ).
To begin to probe the functional consequences of TMEM127 mutations, we generated wild-type and mutant constructs tagged with Flag (either at the N or C terminus of the protein) or hemagglutinin (HA; N terminus) epitopes. We detected a single product of approximately 26 kDa in HEK293 cells that were transfected with the wild-type constructs (Fig. 1a,b) . However, we were unable to detect a translation product from the mutant constructs in these cell lines (Fig. 1a) , despite equivalent transfection efficiencies ( Supplementary  Fig. 4a ). These data suggest that TMEM127-mutant proteins are not expressed in these cells, which supports a loss-of-function effect of these variants. Using confocal microscopy, we found that TMEM127 localizes to the plasma membrane and the cytoplasm, both in a punctate pattern and as perinuclear clusters (Fig. 1c and Supplementary TMEM127 immunoreactivity determined by Flag or HA (red) is present both at the plasma membrane (left) and cytoplasm, with punctate (middle and right) or perinuclear (right, arrows) signals, but is absent from the nucleus (DAPI, blue). These distinct staining patterns were observed with the various constructs in at least three independent experiments (supplementary Fig. 4b ). Plasma membrane-associated TMEM127 distribution was detected on average in 38% (± 13% (s.d.), n = 200) of cells under standard culture conditions. A similar variance in the percentage of plasma membraneassociated signal was noted for each of the constructs. Colocalization studies showed that TMEM127 associates with a subpopulation of vesicular organelles corresponding to early endosomal structures labeled by the GTPase Rab5 (Fig. 2a) ; with the Golgi, labeled with both syntaxin 6 ( Fig. 2b) and N-acetylgalactosaminyltransferase-2 ( Supplementary Fig. 5a ); and with lysosomes ( Supplementary Fig. 5b ). We further found that association of TMEM127 with the plasma membrane was enhanced by inhibition of endocytosis 7 ( Fig. 2c) , whereas increasing pH in the culture medium partially trapped TMEM127 in endosomal structures 7 (Fig. 2d) . These findings suggest that TMEM127 associates dynamically with endosomes and may participate in protein trafficking between the plasma membrane, Golgi and lysosomes. We used microarray-based expression profiling to define the transcription signature of TMEM127-mutant tumors. Profiles from eight samples carrying three distinct mutations in TMEM127, as well as additional pheochromocytomas with mutations in other pheochromocytoma susceptibility genes (tumors in 8 RET, 4 NF1, 8 VHL and 15 SDHB or SDHD mutants), were analyzed by unsupervised and supervised methods (Supplementary Table 6), as previously described 8 .
In this sample set, we confirmed the cluster association between the TMEM127-mutant tumors and pheochromocytomas with NF1 and RET mutations suggested by our earlier study of FP-linked tumors 3 . The gene set enrichment analysis (GSEA) algorithm 9 used to identify pathways associated with the TMEM127-mutant tumor signature revealed high statistical association with kinase receptor signals ( Table 2 and Supplementary Fig. 6a ), which had been previously linked to NF1 and RET mutants 3, 8 . This pattern differed from the expression profiles of pheochromocytomas with mutations in VHL, SDHB or SDHD genes, which were uniquely enriched for transcripts involved in the response to hypoxia ( Table 2 and Supplementary Fig. 6b ) 8 .
To further evaluate these findings, we knocked down TMEM127 expression by short interfering (si) or short hairpin (sh) RNA (Supplementary Fig. 6c ). In agreement with the results of the GSEA analysis, HIF1α and its targets were not induced by TMEM127 downregulation in HEK293 or HeLa cells (Supplementary Fig. 6d ). To explore the putative functional relationship between TMEM127-and Expansion of endosomal structures is seen both for HA-TMEM127 and Rab5. Bars, 5 µm.
l e t t e r s
NF1-mutant tumors, we began by examining RAS activation, the hallmark of NF1 loss 10 . TMEM127 depletion by two distinct shRNA sequences did not increase RAS activity (Fig. 3a) . Likewise, AKT phosphorylation, a surrogate for PI3K activity that is enhanced by both NF1 11 and RET 12 mutations, was not increased after TMEM127 knockdown ( Fig. 3b and Supplementary Fig. 7a ). Deregulation of mTOR, a target of several kinase receptor pathways 13 , is also a feature of NF1 loss 14 . This fact, combined with the kinase receptor signature shown by TMEM127-mutant tumors 3 , prompted us to investigate the effects of TMEM127 on mTOR signaling. mTOR operates as two functionally distinct complexes, mTORC1 and mTORC2 (refs. 13,15) . mTORC1 promotes cell growth and protein translation and phosphorylates 4EBP1 and S6K. The cellular role of mTORC2 is less clear, and its best known substrate is AKT 15 . As shown above, TMEM127 depletion did not affect AKT activation (Fig. 3b) . Likewise, enforced expression of TMEM127 did not change AKT phosphorylation (Fig. 3c) , suggesting that mTORC2 is not involved in this signal. In contrast, TMEM127 knockdown led to increased phosphorylation of 4EBP1 in various cell lines (Fig. 3d) . These effects were observed with distinct TMEM127 shRNA target sequences (Fig. 3e) and were independent of serum in HEK293 (Fig. 3f ) and A2058 cells (Supplementary Fig. 7b) . Conversely, enforced expression of TMEM127 using independent constructs led to reduced mTORC1 signaling ( Fig. 3g and Supplementary Fig. 7c) . Consistent with the observation that mTORC1 is a critical regulator of cell growth and size in many species 16 , we found that TMEM127 knockdown cells were larger ( Fig. 3h and Supplementary Fig. 7d ) and proliferated at higher rates compared to control cell lines (Fig. 3i  and Supplementary Fig. 7e) . In contrast, cell proliferation was reduced in cells overexpressing TMEM127 (Supplementary Fig. 7f) . To determine the relevance of these findings in primary tumors, we examined lysates from TMEM127-mutant pheochromocytomas and found increased phosphorylation of S6K compared to normal adrenal medulla or tumors without a TMEM127 mutation (Fig. 3j) . In agreement with the reported effects of NF1 on mTOR 14 , one NF1-mutant pheochromocytoma showed elevated S6K phosphorylation, comparable to the levels seen in tumors with a TMEM127 mutation. Collectively, these results suggest that TMEM127 contributes to controlling mTORC1 signals and they also support a role for TMEM127 as a tumor suppressor.
To further determine the extent to which TMEM127 influences mTOR regulation, we tested the effect of amino acids, which are powerful modulators of mTOR activity that supersede the actions of other regulators of this pathway 17 . Two independent TMEM127-specific shRNA sequences led to increased phosphorylation of the mTORC1 target S6K in 293E cells under both amino acid-starved and amino acid-rich conditions (Fig. 4a) . In agreement with these findings, overexpression of TMEM127 decreased phosphorylation of mTORC1 targets after amino acid repletion ( Fig. 4b and Supplementary Fig. 7g ). To further characterize the interplay between mTOR and TMEM127, we co-expressed Myc-mTOR and HA-TMEM127 in HEK293T cells and examined their localization by confocal microscopy. In the absence of amino acids, Myc-mTOR, like endogenous mTOR, localized diffusely within the cytoplasm, but upon amino acid exposure, it became clustered to the perinuclear region of the cell (Fig. 4c) , a required step for its activation by Rheb1 (ref. 17) . We found that TMEM127 localized to the same cellular compartment as that of amino acid-activated mTOR (Fig. 4c) . Notably, Myc-mTOR perinuclear localization after amino acid stimulation was significantly more pronounced in cells coexpressing TMEM127 than in control cells not overexpressing this gene (93.4 ± 12% (s.d.) versus 64.3 ± 12%, respectively; P < 0.001); Supplementary Fig. 8 ). This finding suggests that the effects of TMEM127 on mTOR may be compartment-specific and may influence mTOR subcellular localization.
In summary, we identified TMEM127 as a new tumor suppressor gene associated with pheochromocytoma development. Similar to 
other mutations reported in these tumors, all TMEM127 mutations were present in the germline 1 . Our results suggest that TMEM127 limits mTORC1 activation and that it occupies the same intracellular domain as active mTOR. Notably, a component of the trans-Golgi network that shuttles between the plasma membrane and the endomembrane system has recently been implicated in cancer through a mechanism involving modulation of mTOR signals 18 . Taken together with other recent evidence 19, 20 , our data give further support to an emerging role of the endomembrane and vacuolar network in mTOR regulation and cancer. Future studies using in vivo models should determine whether mTOR activation is sufficient to explain the tumor phenotype resulting from TMEM127 mutations. Finally, our results support the notion that disruptions of TMEM127 function could be the underlying basis for tumors with an aberrant mTOR pathway and validate the relevance of hereditary tumor models to shed light on cell growth-related signals.
METHODs
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Accession codes. All datasets are available under GEO accession GSE19987.
Requests for materials: dahia@uthscsa.edu. HA indicates TMEM127 expression. β-actin is the loading control. P-S6K, phosphorylated S6 kinase at residue T389; P-S6, phosphorylated S6 at residues S235-236; P-4EBP1, phosphorylated 4EBP1 at residues T37-46; S6K, total S6 kinase. (c) HEK293T cells cotransfected with HA-TMEM127 and Myc-mTOR were serum-starved overnight, depleted of amino acids for 1 h followed by re-exposure for 15 min (AA+). Cells were fixed and stained with antibodies specific for HA (green), Myc (red) or DAPI (blue) before imaging. Myc-mTOR was diffusely present in the cytoplasm in the absence of amino acid and became localized to a perinuclear region where TMEM127 was detected after amino acid exposure. Similar results were obtained with two independent TMEM127 constructs. Bars, 5 µm. DNA and RNA isolation. Blood and tumor DNA was isolated using the Qiagen Genomic-tip system or the Qiagen Gentra Puregene Cell kit (for paraffinembedded samples) following the manufacturer's protocols. Total RNA was prepared from frozen tumor specimens with TRIzol according to the manufacturer's instructions.
ONLINE METHODs
FP locus sequencing strategy. The FP locus contained 205 genes (NCBI Build 35.1), of which all but 13 had annotation in the RefSeq database (Supplementary Table 1 ). Exon-spanning primers for 85 of these genes were designed for PCR, followed by sequencing using tumor DNA from one of the affected cases (index case of family 1) as a template. Sequence variants that were present in the NCBI SNP database (see URLs) or that did not segregate with the pheochromocytoma phenotype family 1 were not pursued further.
TMEM127 sequencing. Primers spanning the four exons of TMEM127 were used to amplify germline or tumor DNA from 103 pheochromocytoma cases. Formalin-fixed paraffin-embedded tumor samples were analyzed with an independent set of primers. PCR products were purified and directly sequenced by Beckman Coulter Genomics (formerly Agencourt Bioscience) as previously described 3 .
LOH analysis. We performed LOH analysis on 35 pheochromocytomas for which blood and tumor DNA were available: 19 samples were from 6 index cases and 8 of their affected relatives carrying TMEM127 mutations (5 tumors were bilateral). The remaining 16 samples were from cases without mutations in pheochromocytoma susceptibility genes. We used informative chromosome 2 microsatellite markers, as reported previously 8 , and/or SNPs surrounding and within the TMEM127 locus (rs2276650, rs3852673 and rs3739160)for this analysis.
Microarray-based expression profiling and gene-set enrichment analysis. We generated transcription profiles of 50 hereditary and sporadic pheochromocytomas using Affymetrix U133 microarrays and combined these results with previously published data from 76 pheochromocytomas (all datasets available under GEO accession GSE19987) 8 . In total, seven individual 'FP-type' tumors were available in the expanded dataset. Combined transcription data were normalized and used for unsupervised and supervised analysis as previously reported 8 . GSEA was performed on the supervised dataset using GSEA v2.0 default parameters 9 . We did paired analyses between the FP mutants and (i) each known hereditary pheochromocytoma class; (ii) all of the hereditary tumors mentioned above combined; or (iii) tumors without an identifiable TMEM127 mutation.
Real-time PCR.
We did quantitative real-time PCR in cDNA isolated from 23 pheochromocytomas or cell lines, as indicated. We also performed real-time quantitative PCR in triplicate using the iCycler iQ Real-Time PCR Detection System (Bio-Rad). TBP (the gene encoding the TATA-box binding protein) was used as reference for calculation of 2 −∆∆ Ct as previously reported 23 .
RNA blot. We conducted RNA blotting using the multitissue blot set (Clontech MTN Blot) containing 2 µg poly(A) RNA from various human tissues and probed with a full-length TMEM127 insert as described previously 24 .
Clones and constructs. cDNA from TMEM127-mutant tumors or a full-length TMEM127 clone (pCMV6-XL5-TMEM127; OriGene) were used as templates to generate constructs tagged at the N terminus and C terminus with a Flag epitope sequence present in one of the primers. We generated the mutant constructs M158 and M99 ( Table 1 ) by mutagenizing the wild-type sequence using the QuikChange mutagenesis kit (Stratagene) or from an affected individual's tumor cDNA, respectively. We cloned wild-type and/or mutant constructs into the pMSCV retroviral-based vector 25 , pHM6 plasmid (HA tag at the N terminus) and pEGFP-C2 vector. The corresponding empty vector was used as control for transfections. We selected stable clones by G418 (pHM6) or GFP-sorting (MSCV and pEGFP-C2). The Myc-mTOR construct was obtained from Addgene (plasmid 1861), as published 26 .
siRNA and shRNA. siRNA oligonucleotides directed to the TMEM127 sequence were obtained from Dharmacon. We used GFP siRNA as the control as previously described 8 . We transfected 100 nm of each siRNA duplex with Lipofectamine 2000 and verified knockdown efficiency by real-time PCR from RNA harvested 48 h after transfections. We obtained protein lysates of efficient knockdown samples 72 h post-transfection. Two of the four siRNA, siT1 and siT2 oligonucleotides (Supplementary Table 7) , downregulated TMEM127 expression by over 70% of baseline levels and were used for further experiments.
Four retrovirus-based shRNA sequences targeting TMEM127 in pRSHuSH vector were obtained from OriGene. Two sequences, shT1 and shT2 (Supplementary Table 7) , independent of siT1 and siT2, effectively (>60%) downregulated TMEM127 expression as determined by real-time PCR. Control shRNA constructs targeting GFP in the HuSH pRS plasmid vector were also obtained from OriGene and were used for transfection of HEK293T, HEK293, 293E, HeLa and A2058 cell lines. Stable cell pools were selected with puromycin for 4-10 d and used within 3 weeks of selection. We determined efficiency of TMEM127 knockdown as described above.
Cell culture and transfections. 293E cells were a kind gift of J. Blenis (Harvard Medical School). We cultured 293E, HEK293, HEK293T, HeLa and A2058 melanoma cells were in DMEM medium and 10% FBS serum supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin. Cells were serum starved overnight and exposed to regular serum (10%) after 10 to 30 min, as described in the text. We measured amino acid response by exposing cells serum-starved overnight to Dulbecco's PBS buffer supplemented with 4.5 g/l glucose for 1 h (amino acid starvation period) followed by re-exposure to a full amino acid mixture (1× MEM amino acids solution) for 15 min, after which we harvested the cells.
Retroviral transduction was carried out by an initial co-transfection of the relevant constructs along with pKAT and vSVG plasmids into HEK293T cells using Lipofectamine 2000. We collected viral supernatants at 48 h and 72 h after transfection and used these to transduce target cells in the presence of polybrene. We harvested transduced cells at 48 h for RNA and at 72 h for protein analysis, or selected cells as described above. All other transfections were performed with Lipofectamine.
Immunoblots. Whole cell lysates from tumors and normal adrenal medullas were obtained as previously described 27 . Cell lines were lysed in buffer containing 20 mM HEPES (at pH 7.4), 10% glycerol, 1% NP-40 and protease inhibitors. The soluble fractions were isolated by centrifugation. Approximately 50 µg of whole-cell lysates were used on 12% SDS-polyacrylamide gels, transferred to polyvinylidene fluoride (PVDF) membranes and hybridized with the antibodies listed above according to the manufacturer's instructions. Filters were developed with a chemiluminescence assay (West Pico, Pierce) and exposed to X-ray film (Kodak).
RAS activation assays.
We cultured HEK293, HeLa or 293E (in the presence or absence of serum) cells expressing either shTMEM127 or shGFP controls as indicated above. We incubated 400 µg of cell lysates with RAF1-GST fusion protein for 3 h at 4 °C, washed immunoprecipitates in GST buffer and detected RAS-GTP using an antibody to RAS as previously described 25 . Total levels of RAS protein and β-actin present in the whole cell lysates were determined in parallel to ensure equal loading. We conducted these experiments five times.
Proliferation assays. We seeded stable HEK293 or A2058 TMEM127 knockdown or control (shGFP) cells at 5 × 10 4 cells per well of a six-well plate in normal (10%) growth medium or 1% serum. Daily, for 3 d, we trypsinized the cells and counted live cells on triplicate plates by Trypan blue exclusion. We also determined proliferation rates of 293E and HEK293T cells with TMEM127 knockdown or overexpression and respective control cells in the presence or absence of serum using a method based on DNA binding to a fluorescent reagent (CyQUANT NF, Invitrogen). The resulting fluorescence was measured on a microplate reader (Optima) following the manufacturer's guidelines. We conducted these experiments three times in triplicate.
Flow cytometry. Stable TMEM127 knockdown on HEK293 and A2058 and their respective control cell lines were fixed in ethanol, stained with propidium iodide and analyzed by forward-scattering fluorescence-activated cell sorting (FACS) to determine cell size 28 . We repeated these experiments three times.
Immunofluorescence microscopy. We plated HEK293T cells overexpressing empty MSCV-TMEM127-N-Flag or MSCV alone, or 293E cells expressing HA-TMEM127 or HA-empty vector, on poly-D-lysine-coated glass coverslips in 24-well tissue culture plates. After 24 h, cells were serum-or amino acid-starved and stimulated as described above, rinsed with PBS and fixed in 4% paraformaldehyde in PBS. The coverslips were permeabilized and blocked with 5% horse serum and 0.2% Triton X-100 in PBS, and incubated with primary antibody (to Flag M2, HA.11, Syntaxin 6, Rab or Myc) at the recommended dilutions in blocking buffer overnight at 4 °C, rinsed and incubated with secondary antibody (conjugated to Alexa 488, Cy3 or Cy5). We briefly exposed the slides to DAPI and mounted the coverslips on glass slides using Vectashield (Vector Laboratories) for imaging. Specificity of the signal was determined by omission of the primary antibody in control coverslips. Additionally, we conducted Golgi staining using the Organelle Lights Golgi-RFP (Invitrogen), in which the Golgi component N-acetylgalactosaminyltransferase-2 is fused to red fluorescence protein (RFP) in a baculovirus-based construct and transduced into target cells (293E stably expressing HA-TMEM127 or an empty control vector), following the manufacturer's instructions. Images were acquired by laser scanning confocal microscopy with an Olympus FV1000 imaging system and IX81 microscope. We used the UPLANAPO ×60 oil objective (1.42 NA) for all datasets and applied an additional electronic zoom of 3. Excitation and emission signals were, respectively, 405 and 425 ± 50 nm (s.d.) for DAPI, 488 and 500 ± 35 nm for Alexa 488 or GFP, and 543 and 560-660 nm for Cy3. Quantitative colocalization was calculated using intensity correlation analysis (ICA), as described 29 . The difference from the mean for each pixel intensity was first calculated for each channel (R i − R mean and G i -− G mean , where R is the red pixel intensity and G is the green pixel intensity). The product of the differences from the mean [PDM = (R i − R mean ) × (G i − G mean ]) is positive when both red and green pixel intensities are either above or below their respective means (that is, when pixel intensities vary synchronously). We did ICA on single optical sections ~0.4 µm thick for at least seven cells from multiple independent fields and three independent experiments.
Colocalization studies with lysosomes were performed in live HEK293T cells transfected with GFP-TMEM127. We then plated the cells on polyd-lysine-coated glass plates (TissueTek) in medium without phenol red. Fifteen minutes before imaging, we added fresh medium containing 25 nM LysoTracker Red-DND 99 (Invitrogen). Live images were acquired on a confocal microscope (LSM 510; Carl Zeiss MicroImaging, Inc., Software 3.2 SP2.) with a ×63/1.4 NA plan-apochromat objective. Excitation and emission signals for GFP and were, respectively, 488 and 500 ± 35 nm and 543 and 560-660 nm. To estimate the fraction of TMEM127 associated with the plasma membrane, we defined a fluorescence signal that was within 5 µm of the membrane and was 5% higher than the background fluorescence of plasma membraneassociated TMEM127. We measured pixel intensities in single optical sections acquired on a confocal microscope, as described above. The fraction of cells with a plasma membrane-associated signal was determined in relation to TMEM127-expressing cells that did not show this pattern. Data was obtained from HEK293T cells transfected with our four TMEM-tagged constructs (N-and C-Flag, N-HA and GFP).
For endocytosis inhibition, we processed 293E cells stably expressing HA-TMEM17 as previously described 7 . Briefly, we rinsed cells in buffer A (20 mM HEPES, pH 7.4, 140 mM NaCl, 1 mM CaCl 2 and 1 mM MgCl 2 ) and incubated them in hypotonic medium (buffer A diluted 1:1 in water) for 5 min and then in buffer A for 2 h; we then fixed and stained the cells as described above. Control cells were maintained in regular medium. Endosome 'trapping' is based on protein retention in endosomal structures by inhibition of acidification in the culture medium and was performed by incubating HA-TMEM17-expressing 293E cells in medium supplemented with 50 mM ammonium chloride or equal volume of vehicle for 2 h (ref. 7) fixed and stained as described above.
We colocalized mTOR and TMEM127 cby co-transfection of a Myc-tagged mTOR construct and HA-TMEM127, Flag-TMEM127 or GFP-TMEM127 in HEK293T cells. After 24 h, cells were serum-and amino acid-starved, and then re-exposed to amino acids and were fixed and stained as described above. We conducted comparative experiments by transfection of Myc-mTOR in HEK293T cells not overexpressing TMEM127 that were treated in an identical manner. Distribution of Myc-mTOR localization in transfected cells was analyzed by scoring three distribution patterns: diffuse cytoplasmic, perinuclear only or vacuolar clusters (Supplementary Fig. 8 ) both in Myc-mTOR and TMEM127 co-transfection and Myc-mTOR control cells. Two independent observers (Y.Q. and P.L.M.D.) scored at least 200 cells from three independent experiments. Statistical significance was measured using the chi-square test.
URLs. NCBI SNP database, http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp &cmd=search&term=snp.
